Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

Author： Jaakkola Tiina Backman Janne Neuvonen Mikko Niemi Mikko Neuvonen Pertti

ISSN： 0031-6970

Source： European Journal of Clinical Pharmacology, Vol.62, Iss.7, 2006-07, pp. : 503-509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 3, 2016-05 ,pp. : 170-179

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis

By Główka Franciszek

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 36, Iss. 3, 2011-09 ,pp. : 167-173

Springer Publishing Company

Access to resources Recommend Favorite

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance

By Kirchheiner Julia Roots Ivar Goldammer Mark Rosenkranz Bernd

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1209-1225

Adis International

Access to resources Recommend Favorite

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

Current Drug Metabolism, Vol. 10, Iss. 9, 2009-11 ,pp. : 1009-1047

Bentham Science Publishers

Access to resources Recommend Favorite

CYP2C8 and antimalaria drug efficacy

By Gil JP Gil Berglund E

Pharmacogenomics, Vol. 8, Iss. 2, 2007-02 ,pp. : 187-198

Future Medicine

Access to resources Recommend Favorite